Ipsen Global - A Biopharmaceutical Company | Innovation for Patient Care
Focus. Together. For patients & society
What we do
Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.
Making a Difference Where it's Needed Most
Oncology
people die from cancer every year, making it a leading global killer
Rare Diseases
people globally are living with a rare disease, most of whom have no approved treatment
Neuroscience
people worldwide live with spasticity, yet access to treatment remains limited
Underserved Population
of rare diseases begin in childhood yet most go undiagnosed or untreated
Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.
David Loew
CEO
The latest highlights from Ipsen
Find out what’s been going on at Ipsen of late – with press releases, trending stories, events, and more.
Corporate
21 August 2026
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline](/content/press-release/ipsen-completes-acquisition-of-kartos-therapeutics-strengthening-late-stage-oncology-pipeline-3348882/index.html)
Financial
30 July 2026
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance](/content/press-release/ipsen-delivers-excellent-h1-2026-results-and-upgrades-its-full-year-guidance-3335743/index.html)
Rare Diseases
22 July 2026
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline](/content/press-release/ipsen-completes-acquisition-of-memo-therapeutics-ag-adding-first-in-class-asset-to-ipsens-rare-disease-pipeline-3331074/index.html)
Rare Diseases
13 July 2026
IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb…](/content/press-release/iqirvo-demonstrates-statistically-significant-improvement-in-alp-normalization-in-patients-with-pbc-in-phase-iiib-elspire-study-3325891/index.html)
Neuroscience
09 July 2026
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both…](/content/press-release/dysport-is-the-first-botulinum-toxin-to-achieve-positive-topline-phase-iii-results-in-both-episodic-and-chronic-migraine-3324543/index.html)
Rare Diseases
28 May 2026
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC](/content/press-release/new-late-breaking-data-reinforces-iqirvos-impact-on-alp-fatigue-and-pruritus-in-pbc-3302504/index.html)
Neuroscience
19 May 2026
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with…](/content/press-release/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysport-and-botox-in-adults-with-upper-limb-spasticity-3297909/index.html)
How Ipsen helps
Ipsen focuses on three key therapeutic areas, leveraging all our resources to help patients with unmet medical needs.
Oncology
Ipsen has been working in oncology since 1986, and now has a portfolio that includes treatments for neuroendocrine tumor (NETs), and cancers of the kidney, liver, pancreas, thyroid, prostate and breast.](/content/oncology/index.html)
Rare Disease
Ninety-four percent of rare medical conditions still have no treatment. We are committed to finding treatments for extremely rare bone diseases and disorders, growth disorders, rare cancers, rare liver disease and rare neurogenetic disorders.](/content/rare-disease/index.html)
Neuroscience
Ipsen draws on 30 years of expertise in toxins and neuroscience research to support children and adults suffering from debilitating and degenerative neurological conditions.](/content/neuroscience/index.html)
Science with Purpose
At Ipsen we believe in advancing science with purpose. With our unique size and specialized expertise, we accelerate innovation navigating development and regulatory pathways to bring transformational new medicines to patients around the world.
Our Partnerships
At Ipsen, we believe that partnerships create possibilities. We seek to build partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.
Commitment to Sustainability
At Ipsen, we put our actions into motion through our structured approach to sustainability.
Join us
Ipsen offers a multitude of exciting opportunities for talented and motivated people in careers ranging from medial and clinical research to sales, marketing, finance, IT, HR and legal services. We are committed to providing our employees with a workplace that is welcoming, challenging and inclusive.